作者
Arnav Agarwal, Beverley J Hunt, Miriam Stegemann, Bram Rochwerg, François Lamontagne, Reed AC Siemieniuk, Thomas Agoritsas, Lisa Askie, Lyubov Lytvyn, Yee-Sin Leo, Helen Macdonald, Linan Zeng, Ahmed Alhadyan, Al-Maslamani Muna, Wagdy Amin, André Ricardo Araujo da Silva, Diptesh Aryal, Fabian A Jaimes Barragan, Frederique J Bausch, Erlina Burhan, Carolyn S Calfee, Maurizio Cecconi, Binila Chacko, Duncan Chanda, Vu Quoc Dat, An De Sutter, Bin Du, Stephen Freedman, Heike Geduld, Patrick Gee, Muhammad Haider, Matthias Gotte, Nerina Harley, Madiha Hashmi, David Hui, Mohamed Ismail, Fyezah Jehan, Sushil K Kabra, Seema Kanda, Yae-Jean Kim, Niranjan Kissoo, Sanjeev Krishna, Krutika Kuppalli, Arthur Kwizera, Marta Lado Castro-Rial, Thiago Lisboa, Rakesh Lodha, Imelda Mahaka, Hela Manai, Marc Mendelson, Giovanni Battista Migliori, Greta Mino, Emmanuel Nsutebu, Jessica Peter, Jacobus Preller, Natalia Pshenichnaya, Nida Qadir, Shalini S Ranganathan, Pryanka Relan, Jamie Rylance, Saniya Sabzwari, Rohit Sarin, Manu Shankar-Hari, Michael Sharland, Yinzhong Shen, Joao P Souza, Ronald Swanstrom, Tshokey Tshokey, Sebastian Ugarte, Timothy Uyeki, Evangelina Vazquez Curiel, Sridhar Venkatapuram, Dubula Vuyiseka, Ananda Wijewickrama, Lien Tran, Dena Zeraatkar, Jessica J Bartoszko, Long Ge, Romina Brignardello-Petersen, Andrew Owen, Gordon Guyatt, Janet Diaz, Leticia Kawano-Dourado, Michael Jacobs, Per Olav Vandvik
发表日期
2020/9/4
期刊
bmj
卷号
370
出版商
British Medical Journal Publishing Group
简介
Updates
This is the fourteenth version (thirteenth update) of the living guideline, replacing earlier versions (available as data supplements). New recommendations will be published as updates to this guideline.
Clinical question
What is the role of drugs in the treatment of patients with covid-19?
Context
The evidence base for therapeutics for covid-19 is evolving with numerous randomised controlled trials (RCTs) recently completed and underway. Emerging SARS-CoV-2 variants and subvariants are changing the role of therapeutics.
What is new
The guideline development group (GDG) defined 1.5% as a new threshold for an important reduction in risk of hospitalisation in patients with non-severe covid-19. Combined with updated baseline risk estimates, this resulted in stratification into patients at low, moderate, and high risk for hospitalisation. New recommendations were added for moderate risk of hospitalisation …
学术搜索中的文章
A Agarwal, BJ Hunt, M Stegemann, B Rochwerg… - bmj, 2020
F Lamontagne, T Agoritsas, H Macdonald, YS Leo… - bmj, 2020